France challenges EU approval process for GMOs


Brussels/Paris – The French EU presidency is challenging the current EU process for market authorisation of genetically modified organisms (GMOs). At the beginning of the French term, environment minister Jean-Louis Borloo announced that a new ad-hoc committee will define additional criteria for the risk assessment procedure carried out by the European Food Safety Authority (EFSA).

In addition to the scientific evaluation of whether GMOs pose a potential danger to human health or the environment, France and other GMO-sceptic EU member states are seeking to implement an assessment of the socio-economic impact of GMO acreage, its usefulness, and an improved examination of its long-term effects on the environment. Borloo’s announcement was accompanied by demands from some EU member states to permit national market bans on GMO acreage. Experts expect another de facto-GMO moratorium if the new procedures are given the green light by the Commission. The Commission, however, which had already established an expert group to review its GMO policy, showed no interest in changing the current approval system. While France and GMO-sceptic governments have sought to weaken EFSA to gain more control over the assessment process that precedes GMO market approval, the Commission has strengthened EFSA’s position.

Commission stands behind EFSA

“France’s move is intended to nullify the meaningful separation of scientific and political decisionmaking on GMOs,” EU insiders told EuroBiotechNews. “Once the addition of political topics to the risk assessment prodedure leads to a situation where the EFSA appears to be undecided, GMO sceptics will say: ‘Look, there’s dissent over the safety of GMOs.” The battle that GMO-sceptic member states are waging against the current system of GMO approval and EFSA, which has yet to reject a market application on scientific grounds, will come to a head in December. One week before Christmas, EU environment
ministers will ask EU heads of state to change the criteria for GMO risk assessment. At the same time, EFSA is expected to publish a scientific opinion on the safety of npt2, an antibiotic marker used in BASF Plant Science’s GM potato Amflora (see p. 10). If positive, the scientific statement, which was requested by the Commission, will lead to the first approval for commercial acreage of a GM crop in Europe since 1998. EU insiders believe the Commission systematically prepared EFSA for the attack under the French presidency, and say the authority was told to update its guidelines
for GMO risk assessment before France took over. EFSA has also moved to address criticism about transparency; in June, the authority invited experts to lend their expertise to its decisions.



Stockholm/Suresnes - Swedish BioInvent International AB and French Laboratoires Servier are working together on an oncology target. Under the terms of the agreement, Servier will engage BioInvent to screen its proprietary library...



Romainville – Cellectis SA has completed its acquisition of Cellartis AB, which provides stem cell-based in vitro R&D tools, in a cash and stock deal valued at €29.1m (US$39.9m). Cellartis shareholders received 1.9 million...



Paris – One of the biggest European biotech deals of 2011 is now sealed. As announced in September, the shareholders of French genome engineering specialist Cellectis approved the takeover of Swedish Cellartis, the European...



Paris - Sanofi and MS patients can breathe a sigh of relief. At an MS congress in Amsterdam, the company presented impressive results of a phase III trial comparing alemtuzumab with subcutaneous Rebif interferon beta-1a in 581...



Paris/Boulder – French drugmaker Servier has secured the rights for two miroRNA drug candidates from US-biotech MiRagen. Both companies clinched a partnership agreement under which Servier would fund the research, development and...



Paris/Hyderabad – Sanofi Aventis believes in India. The pharmaceutical company announced the opening a state-of-the-art vaccine manufacturing facility, believed to be Asia's biggest, in March 2012. In the coming years Sanofi will...



Paris – Nanobiotix S.A. is entering the clinical stage with its NanoXray nano­particle therapy, which aims to increase the efficacy of radiotherapy without increasing dosage. In mid-September, the French nano­medicine company...

Sweden, FranceFrance


Paris – For €16.4m in cash and roughly €12m in shares, French genome engineering specialist Cellectis has taken over Swedish Cellartis. Cellartis is the European leader in stem cell-derived cardiomyocytes and hepatocytes. With 62...

Germany, FranceFrance


Luxembourg - Disorientation reigns in green biotechnology in Europe. Two decisions by the European Court of Justice regarding genetically modified crops point in different directions. On Thursday the judges left the opponents of...

Displaying results 11 to 20 out of 268

< Previous 11-20 Next >

© 2007-2016 BIOCOM


Current issue

All issues

Product of the week


Stock list

All quotes


  • PLETHORA (UK)3.38 GBP12.67%
  • ALMIRALL (E)14.43 EUR7.93%


  • 4SC (D)2.59 EUR-20.31%
  • FORMYCON (D)20.15 EUR-4.37%


  • GALAPAGOS (B)51.86 EUR30.7%
  • NICOX (F)11.00 EUR28.7%
  • GENMAB (DK)1177.00 DKK22.2%


  • MOBERG PHARMA (S)38.00 SEK-21.8%
  • 4SC (D)2.59 EUR-21.5%
  • FORMYCON (D)20.15 EUR-18.0%


  • KARO BIO (S)30.60 SEK1981.6%
  • CHRONTECH PHARMA (S)0.34 SEK1600.0%
  • NICOX (F)11.00 EUR491.4%


  • BB BIOTECH (D)44.03 EUR-84.5%
  • BIOTEST (D)17.15 EUR-78.1%

No liability assumed, Date: 29.05.2016


All Events



Biomedica 2016

Basel (CH)

Chemspec Europe 2016